The Fellow on Call: The Heme/Onc Podcast
Episode 124: AML Series, Pt 10 - Allogeneic transplant for AML
Dec 11, 2024
Dr. Amar Kelkar, a hematology and oncology expert from Dana-Farber Cancer Institute, delves into allogeneic transplant options for acute myeloid leukemia (AML). He discusses the various conditioning regimens and how to choose the best one for patients. The conversation also highlights the critical role of measurable residual disease testing and maintenance therapies. Kelkar sheds light on graft-versus-host disease and recent advancements in haploidentical transplants, addressing racial disparities in transplant outcomes for better equity.
00:00
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Tailoring conditioning regimens for allogeneic transplant in AML patients is essential based on their age and disease characteristics to optimize outcomes.
- Racial disparities in transplant outcomes highlight the need for improved donor diversity and equitable access to treatment facilities and clinical trials.
Deep dives
Understanding Conditioning Regimens in Transplantation
Myeloablative and reduced-intensity conditioning regimens are crucial in hematopoietic stem cell transplantation. Myeloablative regimens, such as fludarabine and busulfan, involve higher doses aimed at completely ablating bone marrow before transplant. In contrast, reduced-intensity conditioning regimens use lower doses, making them suitable for older patients who may not tolerate aggressive treatment. Recent studies have shown varying outcomes between the two approaches, emphasizing the need to tailor the conditioning strategy based on patient age and specific disease characteristics.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
